85.7 F
San Fernando
Thursday, Nov 30, 2023

Kythera Seeks FDA Approval for Baldness Treatment

Kythera Biopharmaceuticals Inc. has submitted an Investigational New Drug Application to the U.S. Food and Drug Administration for a new treatment for male pattern hair loss. The Westlake biotech plans to conduct human studies on an experimental drug called KYTH-105, or setipiprant. It is an oral drug that blocks the receptors for the substance prostaglandin D2. Research has found that men with male pattern baldness have elevated levels of PGD2. “KYTH-105 represents a unique scientific approach to the treatment of hair loss that has the potential to help millions of men achieve a positive self-image,” Dr. Frederick Beddingfield, Kythera’s chief medical officer, said in a statement. In June, Kythera announced plans to be acquired by Allergan plc in Ireland. Shares closed up 1 cent or a fraction of a percent to $74.87 on the Nasdaq.

Joel Russel
Joel Russel
Joel Russell joined the Los Angeles Business Journal in 2006 as a reporter. He transferred to sister publication San Fernando Valley Business Journal in 2012 as managing editor. Since he assumed the position of editor in 2015, the Business Journal has been recognized four times as the best small-circulation tabloid business publication in the country by the Alliance of Area Business Publishers. Previously, he worked as senior editor at Hispanic Business magazine and editor of Business Mexico.

Featured Articles

Related Articles